Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Over the past decade, the fields of oncology have made great strides in therapies. The development of new therapeutics and increased understanding of the role of the immune system in the development and treatment of cancer has led to increased collaboration between oncologic fields. Recent technologic advancements in radiation therapy (RT), including stereotactic beam radiation therapy (SBRT), have improved local control and offer an alternative to surgery for the control of oligometastatic disease. Immunotherapy has proven a promising therapeutic in the treatment of metastatic disease but treatment resistance remains a significant obstacle in the majority of patients. Together, radiation and immunotherapy offer potential to eliminate metastatic disease, reduce time to recurrence and improve overall survival. Major obstacles to these positive outcomes include high tumor burden, intratumoral heterogeneity, and the negative effects of tumor stroma, to name a few. Multimodality treatments are under heavy investigation. Promising data from clinical trials is emerging to highlight the value of RT in combination with immunotherapy. However, the mechanisms behind their synergistic effects remain to be fully elucidated. This review aims to highlight the existing literature and offers hypotheses to explain mechanisms behind the synergy of RT and immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861265 | PMC |
| http://dx.doi.org/10.21037/jtd.2018.01.130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing immunotherapy efficacy in NSCLC through the combined use of phenelzine and to regulate gut microbial metabolite 5-HIAA.
J Immunother Cancer
September 2025
National Engineering Laboratory for Internet Medical Systems and Applications, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Background: Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.
Methods: ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC.
Neoadjuvant Versus Adjuvant Therapy for Metaplastic Breast Cancer: Insights from the National Cancer Database-Is There a Winning Strategy?
Ann Surg Oncol
September 2025
Department of Surgery,Division of Breast Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: This study analyzed a large national cohort to compare treatment strategies and survival outcomes in metaplastic breast cancer (MtBC), a rare and aggressive subtype with poor treatment response.
Patients And Methods: Adult female patients with MtBC diagnosed between 2006 and 2021 were identified from the National Cancer Database and grouped by chemotherapy sequence (neoadjuvant vs. adjuvant) to evaluate clinical characteristics and survival outcomes.
Stereotactic body radiation therapy or conventional fractionated radiotherapy combined with immune checkpoint inhibitors? From biological perspectives.
Front Immunol
September 2025
Department of Radiation Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
We focused on a paper titled "Radiation with immunotherapy may be a double-edged sword-how can we learn from recent negative clinical trials?", which was published in recently. Herein, we initially provided three complementary viewpoints from biological perspectives involved in the dynamic alterations of the tumor microenvironment, which may contribute to a more comprehensive understanding of the superiority of stereotactic body radiation therapy (SBRT).
View Article and Find Full Text PDFPrevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion.
J Immunother Precis Oncol
August 2025
Tawam Hospital, AlAin, UAE.
Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non-small cell lung cancer (NSCLC). This study aims to investigate the prevalence of , , , , , , and mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region. The systematic literature review was performed using PubMed, Google Scholar, and Google searches to identify studies on the prevalence of , , , , , , and mutations in patients with NSCLC in the MENA region.
View Article and Find Full Text PDFProgression-free survival as a surrogate of overall survival in metastatic or recurrent endometrial cancer: an EORTC gynecologic cancer group study.
Int J Gynecol Cancer
August 2025
12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain.
Objective: The value of progression-free survival as a surrogate marker for overall survival remains a matter of debate. Herein, we evaluated the validity of progression-free survival as a surrogate endpoint for overall survival in trials of recurrent or metastatic endometrial cancer.
Methods: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.